Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir in Severe Ebola Virus Disease
NCT02662855Phase 2Completed
- Sponsor
- Beijing Institute of Pharmacology and Toxicology
- Start
- Nov 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of favipiravir in Ebola virus disease (EVD), sponsored by Beijing Institute of Pharmacology and Toxicology. Started Nov 2014; status: completed.
02
Drugs
favipiravir
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02662855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662855.